Adenocarcinoma of the Pancreas Withdrawn Phase 1 / 2 Trials for Infigratinib (DB11886)

Also known as: Pancreatic adenocarcinoma / Adenocarcinoma Pancreas / Pancreas, Adenocarcinoma / Pancreas Adenocarcinoma / Adenocarcinoma of Pancreas / Adenocarcinoma, Pancreas

IndicationStatusPhase
DBCOND0029532 (Adenocarcinoma of the Pancreas)Withdrawn1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02575508Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic CancerTreatment